Ruud P Dings, PhD

Research Program: Cancer Therapeutics Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Radiation Oncology

Cancer Research Interest

• Disease Site Focus: Cutaneous/Melanoma, GI, Gynecology, Head and Neck, Thoracic/ Lung
• Research Focus Area: Treatment, Carcinogenesis
• Type of Research: Basic
• Research Interest Statement: Primary areas of investigation are aimed at enhancing our understanding of cancer biology to discover and develop improved methods for cancer treatment. Particularly our laboratory major research interest is the tumor microenvironment, with emphasis on the interplay between the immune system and the tumor stroma. This is includes but is not limited to: - Drug discovery, design and development (e.g. cancer, stroma, resistance) - Tumor microenvironment (e.g. vessel normalization, physiology, immunology) - Dysbiosis and carcinogenesis (e.g. microbiome of the GI tract, lung and skin) - Cancer glycobiology (e.g. galectins) - Conventional treatments (e.g. combinations, optimizations, new mechanisms)

Contact Information

• Email Address: RPMDINGS@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• US Department of Defense – W81XWH-21-1-0577
  “Antibiotic-Induced Dysbiosis Promotes Lung Metasta”
  Principal Investigator
  09/30/21 – 09/29/23
• NIH/Nat. Cancer Institute – 1R01CA245083
  “Improvement of cellular immunotherapy during dysbi”
  Principal Investigator
  09/15/21 – 08/31/26
• NIH/Nat. Cancer Institute – 1R01CA238025
  “Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy- Resubmission”
  Principal Investigator
  08/13/19 – 07/31/25

Publications

• Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, [et al., including Dings RPM]. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis. 2022. PMID: 36459240. PMCID: PMC10119234.
• Dings RPM, Kumar N, Mikkelson S, [et al.]. Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activity. Biochemistry and biophysics reports. 2021 28:101116. PMID: 34485713. PMCID: PMC8408429.
• Jenkins SV, Alimohammadi M, Terry AS, [et al., including Dings RPM]. Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. Angiogenesis. 2021. PMID: 33629198. PMCID: PMC8295215.
• Safina I, Alghazali KM, Childress L, [et al., including Dings RPM]. Dendritic cell biocompatibility of ether-based urethane films. Journal of applied toxicology : JAT. 2021. PMID: 33417269. PMCID: PMC8263788.
• Safina I, Al Sudani ZAN, Hashoosh A, [et al., including Dings RPM]. Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells. PloS one. 2021 16(8):e0241882. PMID: 34460818. PMCID: PMC8404976.
• Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, [et al., including Dings RPM]. Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiation research. 2020 194(6):688-697. PMID: 33348372. PMCID: PMC8008989.
• Dadgar S, Troncoso JR, Siegel ER, [et al., including Dings RPM]. Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia (New York, N.Y.). 2020 23(1):49-57. PMID: 33220616. PMCID: PMC7683290.
• Jenkins SV, Robeson MS 2nd, Griffin RJ, [et al., including Dings RPM]. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer research. 2019 79(23):5999-6009. PMID: 31591154. PMCID: PMC6891208.
• Paidi SK, Diaz PM, Dadgar S, [et al., including Dings RPM]. Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. Cancer research. 2019 79(8):2054-2064. PMID: 30819665. PMCID: PMC6467810.
• Boysen G, Jamshidi-Parsian A, Davis MA, [et al., including Dings RPM]. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. International journal of radiation biology. 2019 95(4):436-442. PMID: 30557074. PMCID: PMC6622448.
• Jenkins SV, Nedosekin DA, Shaulis BJ, [et al., including Dings RPM]. Enhanced Photothermal Treatment Efficacy and Normal Tissue Protection via Vascular Targeted Gold Nanocages. Nanotheranostics. 2019 3(2):145-155. PMID: 31008023. PMCID: PMC6470343.
• Jenkins SV, Vang KB, Gies A, [et al., including Dings RPM]. Sample storage conditions induce post-collection biases in microbiome profiles. BMC microbiology. 2018 18(1):227. PMID: 30591021. PMCID: PMC6307155.
• Vargas I, Alhallak K, Kolenc OI, [et al., including Dings RPM]. Rapid quantification of mitochondrial fractal dimension in individual cells. Biomedical optics express. 2018 9(11):5269-5279. PMID: 30460127. PMCID: PMC6238904.
• Diaz PM, Jenkins SV, Alhallak K, [et al., including Dings RPM]. Quantitative diffuse reflectance spectroscopy of short-term changes in tumor oxygenation after radiation in a matched model of radiation resistance. Biomedical optics express. 2018 9(8):3794-3804. PMID: 30338156. PMCID: PMC6191608.
• Nowak-Sliwinska P, Alitalo K, Allen E, [et al., including Dings RPM]. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 21(3):425-532. PMID: 29766399. PMCID: PMC6237663.
• Kore RA, Edmondson JL, Jenkins SV, [et al., including Dings RPM]. Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells. Biochemistry and biophysics reports. 2018 14:104-113. PMID: 29872742. PMCID: PMC5986551.
• Lee DE, Alhallak K, Jenkins SV, [et al., including Dings RPM]. A Radiosensitizing Inhibitor of HIF-1 alters the Optical Redox State of Human Lung Cancer Cells In Vitro. Scientific reports. 2018 8(1):8815. PMID: 29891977. PMCID: PMC5995847.
• Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as Molecular Targets for Therapeutic Intervention. International journal of molecular sciences. 2018 19(3). PMID: 29562695. PMCID: PMC5877766.
• Jenkins SV, Nedosekin DA, Miller EK, [et al., including Dings RPM]. Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2018 34(1):19-29. PMID: 28540812. PMCID: PMC5872830.
• Koonce NA, Griffin RJ, Dings RPM. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. International journal of molecular sciences. 2017 18(12). PMID: 29232825. PMCID: PMC5751273.
• Koonce NA, Juratli MA, Cai C, [et al., including Dings RPM]. Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry. Biochemical and biophysical research communications. 2017 492(3):507-512. PMID: 28822765. PMCID: PMC5743220.
• Vang KB, Safina I, Darrigues E, [et al., including Dings RPM]. Modifying Dendritic Cell Activation with Plasmonic Nano Vectors. Scientific reports. 2017 7(1):5513. PMID: 28710434. PMCID: PMC5511287.
• Alhallak K, Jenkins SV, Lee DE, [et al., including Dings RPM]. Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells. Journal of biomedical optics. 2017 22(6):60502. PMID: 28622395. PMCID: PMC5499259.
• Griffin RJ, Dings RPM, Makhoul I. Further rationale for optimal combined modality treatments. Oncotarget. 2017 8(16):25831-25832. PMID: 28415727. PMCID: PMC5432217.
• Jenkins SV, Nima ZA, Vang KB, [et al., including Dings RPM]. Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. NPJ precision oncology. 2017 1(1):27. PMID: 29872709. PMCID: PMC5871908.